Results 261 to 270 of about 71,938 (313)
Some of the next articles are maybe not open access.
Current Opinion in Genetics & Development, 1991
Progress in understanding the role of dystrophin raises promising hopes for a treatment for Duchenne muscular dystrophy. In addition, great improvements have been made in the ability to diagnose this disease using simple molecular methods.
openaire +2 more sources
Progress in understanding the role of dystrophin raises promising hopes for a treatment for Duchenne muscular dystrophy. In addition, great improvements have been made in the ability to diagnose this disease using simple molecular methods.
openaire +2 more sources
Muscular fatigue in Duchenne muscular dystrophy
Neurology, 1995We used a 4-minute sustained maximum voluntary contraction to investigate fatigability of the anterior tibial muscle in eight healthy boys and 11 boys with Duchenne muscular dystrophy (DMD) (ages 5 to 10 years). Before exercise, the force generation of dystrophic muscle and the compound muscle action potential amplitude were lower and half-relaxation ...
K R, Sharma, M A, Mynhier, R G, Miller
openaire +2 more sources
Echocardiography in duchenne muscular dystrophy
Muscle & Nerve, 1980AbstractThe cardiac function of 36 males with Duchenne muscular dystrophy was evaluated by echocardiography, and the results were compared with the results of other tests of cardiac involvement, including serum creatine kinase isoenzyme evaluation, electrocardiography, chest x‐ray, and physical examination of the heart and lungs.
D, Danilowicz +3 more
openaire +2 more sources
Screening for Duchenne muscular dystrophy
Pediatrics, 1977Recently, it has been suggested that all newborn male infants be screened for Duchenne muscular dystrophy (DMD) by measuring creatine phosphokinase (CPK) levels.1,2 One of the main arguments for this approach is that mothers of affected infants who have no known family history of DMD can be counseled.
A D, Roses, G A, Nicholson, C R, Roe
openaire +2 more sources
Duchenne muscular dystrophy and epilepsy
Neuromuscular Disorders, 2013Cognitive and behavioral difficulties occur in approximately a third of patients with Duchenne muscular dystrophy. The aim of our study was to assess the prevalence of epilepsy in a cohort of 222 DMD patients. Epileptic seizures were found in 14 of the 222 DMD patients (6.3%). The age of onset ranged from 3 months to 16 years (mean 7.8).
Pane M +16 more
openaire +2 more sources
Casimersen for Duchenne muscular dystrophy
Drugs of Today, 2021Duchenne muscular dystrophy (DMD) is a genetic disorder affecting 1 in 5,000 males which causes progressive muscle deterioration, loss of mobility and eventual death, with an average lifespan of around 25 years. While no cure currently exists for DMD, a novel treatment known as antisense-mediated exon skipping therapy has shown great promise.
H, Wilton-Clark, T, Yokota
openaire +2 more sources
Biochemical Society Transactions, 1984
What is Duchenne muscular dystrophy? Duchenne muscular dystrophy is a muscle-wasting condition caused by the lack of a protein called dystrophin. It usually affects only boys. About 100 boys with Duchenne muscular dystrophy are born in the UK each year and there are about 2,500 boys and young men known to be living with the condition in the UK at any ...
openaire +2 more sources
What is Duchenne muscular dystrophy? Duchenne muscular dystrophy is a muscle-wasting condition caused by the lack of a protein called dystrophin. It usually affects only boys. About 100 boys with Duchenne muscular dystrophy are born in the UK each year and there are about 2,500 boys and young men known to be living with the condition in the UK at any ...
openaire +2 more sources
Golodirsen for Duchenne muscular dystrophy
Drugs of Today, 2020Duchenne muscular dystrophy (DMD) is a life-shortening X-linked genetic disorder characterized by progressive wasting and weakening of muscles in boys. Loss-of-function mutations in the DMD gene, which codes for dystrophin, lead to this disease. The majority of mutations in this gene result in the exclusion of one or more exons from the transcript ...
S, Anwar, T, Yokota
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1982
Duchenne's muscular dystrophy (DMD) is a progressive muscle disease that inexorably results in death at about the age of 20 years. Unfortunately, there is no effective therapy for this disease. It is an X-linked recessive disorder that almost exclusively occurs in boys. Classic clinical signs are recognized around the age of 3 to 5 years. The diagnosis
openaire +2 more sources
Duchenne's muscular dystrophy (DMD) is a progressive muscle disease that inexorably results in death at about the age of 20 years. Unfortunately, there is no effective therapy for this disease. It is an X-linked recessive disorder that almost exclusively occurs in boys. Classic clinical signs are recognized around the age of 3 to 5 years. The diagnosis
openaire +2 more sources
Journal of the American Academy of Orthopaedic Surgeons, 2002
Duchenne muscular dystrophy is an X-linked disease of muscle caused by an absence of the protein dystrophin. Affected boys begin manifesting signs of disease early in life, cease walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, surgical, and rehabilitative
openaire +2 more sources
Duchenne muscular dystrophy is an X-linked disease of muscle caused by an absence of the protein dystrophin. Affected boys begin manifesting signs of disease early in life, cease walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, surgical, and rehabilitative
openaire +2 more sources